Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

The Lancet Haematology

Volumn 3, Issue 8, 2016, Pages e379-e387

  Raskob, Gary E ^a   van Es, Nick ^b   Segers, Annelise ^c   Angchaisuksiri, Pantep ^d   Oh, Doyeun ^e   Boda, Zoltan ^f   Lyons, Roger M ^g   Meijer, Karina ^h   Gudz, Ivan ⁱ   Weitz, Jeffrey I ^j   Zhang, George ^k   Lanz, Hans ^k   Mercuri, Michele F ^k   Büller, Harry R ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ITREAS   (Netherlands)

^d MAHIDOL UNIVERSITY   (Thailand)

^e CHA University   (South Korea)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ IVANO FRANKIVSK NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^j MCMASTER UNIVERSITY   (Canada)

^k DAIICHI SANKYO INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; ENOXAPARIN; HEPARIN; PLACEBO; QUINIDINE; VERAPAMIL; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; YOUNG ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; EQUIVALENCE TRIAL (TOPIC); FOLLOW UP; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; DOUBLE-BLIND METHOD; EQUIVALENCE TRIALS AS TOPIC; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PYRIDINES; SURVIVAL RATE; THIAZOLES; VENOUS THROMBOEMBOLISM;

EID: 84994890780     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30057-6     Document Type: Article

References (28)

1. 1 Lee, AY, Levine, MN, Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003), I17–I21.
2. 2 Lyman, GH, Khorana, AA, Kuderer, NM, et al. Venous thromboembolism and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31 (2013), 2189–2204.
3. 3 Lyman, GH, Bohlke, K, Khorana, AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33 (2015), 654–656.
4. 4 Kearon, C, Akl, EA, Ornelas, J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
5. 5 Mandala, M, Falanga, A, Roila, F, et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22 (2011), vi85–vi92.
6. 6 Wells, PS, Forgie, MA, Rodger, MA, Treatment of venous thromboembolism. JAMA 311 (2014), 717–728.
7. 7 Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
8. 8 Schulman, S, Kakkar, AK, Goldhaber, SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
9. 9 EINSTEIN investigators, Bauersachs, R, Berkowitz, SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
10. 10 EINSTEIN–PE Investigators, Büller, HR, Prins, MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
11. 11 Agnelli, G, Buller, HR, Cohen, A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
12. 12 Fuji, T, Fujita, S, Tachibana, S, Kawai, Y, A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 8 (2010), 2458–2468.
13. 13 Raskob, G, Cohen, AT, Eriksson, BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomized double-blind dose-response study. Thromb Haemost 104 (2010), 642–649.
14. 14 Weitz, JI, Connolly, SJ, Patel, I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104 (2010), 633–641.
15. 15 Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
16. 16 Raskob, G, Buller, H, Prins, M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost 11 (2013), 1287–1294.
17. 17 Hokusai-VTE Investigators, Buller, HR, Decousus, H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
18. 18 Schulman, S, Kearon, C, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
19. 19 van Gogh Investigators, Buller, HR, Cohen, AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007), 1094–1104.
20. 20 Rosendaal, FR, Cannegieter, SC, van der Meer, FJM, Briet, E, A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69 (1993), 236–239.
21. 21 Schulman, S, Eriksson, H, Goldhaber, SZ, et al. Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood, 122(suppl), 2013 abstr 582.
22. 22 van Es, N, Di Nisio, M, Bleker, SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 114 (2015), 1268–1276.
23. 23 Lee, AY, Levine, MN, Baker, RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003), 146–153.
24. 24 Hull, RD, Pineo, GF, Brant, RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006), 1062–1072.
25. 25 Meyer, G, Marjanovic, Z, Valcke, J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002), 1729–1735.
26. 26 Deitcher, SR, Kessler, CM, Merli, G, Rigas, JR, Lyons, RM, Fareed, J, Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12 (2006), 389–396.
27. 27 Lee, AY, Kamphuisen, PW, Meyer, G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314 (2015), 677–686.
28. 28 Prins, MH, Lensing, AW, Bauersachs, R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J, 11, 2013, 21.